Merck
4Q Revenues: $10.4 billion (+3%)
4Q Loss: $872 million (loss of $594 million 4Q16)  
FY Revenues:$40.1 billion (+1%)
FY Earnings: $2.6 billion (-34%)
Comments: Pharmaceutical sales increased 4% to $9.3 billion in the quarter, driven primarily by significant growth of KEYTRUDA, up 166% to $1.3 billion, reflecting continued launches with new indications globally. Sales of GARDASIL were $633 million, up 17% in the quarter and include approximately $115 million for the partial replenishment of doses of GARDASIL 9 that were borrowed from the U.S. CDC Pediatric Vaccine Stockpile in the third quarter. Januvia sales were $1.5 billion, up 1%. Zetia/Vytorin sales were down 42% to $509 million in the quarter due to loss of U.S. market exclusivity. Sales of PROQUAD, M-M-R II and VARIVAX were flat at $403 million. ISENTRESS sales were $308 million, down 9% in the quarter. ZEPATIER sales were up 29% to $296 million, due to ongoing launches across Europe and Asia Pacific. Revenue in the fourth quarter and full year of 2017 was unfavorably affected by approximately $125 million and $260 million, respectively, from lost sales in certain markets related to the cyber-attack that occurred in June.